Jump to content

AXS-17

Add links
From Wikipedia, the free encyclopedia

AXS-17
Clinical data
Other namesAXS17; BAER101; AZD7325; AZ-7325; AZ7325
Drug classGABAA receptor positive allosteric modulator; Nonbenzodiazepine
ATC code
  • None
Identifiers
  • 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H19FN4O2
Molar mass354.385 g·mol−1
3D model (JSmol)
  • CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC=C3F)OC
  • InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25)
  • Key:KYDURMHFWXCKMW-UHFFFAOYSA-N

AXS-17, also known as BAER-101 or as AZD-7325, is a GABAA receptor positive allosteric modulator and nonbenzodiazepine which is under development for the treatment of anxiety disorders and absence epilepsy.[1][2][3] It is or was also under development for autism spectrum disorder, fragile X syndrome, and other neurological disorders, but no recent development has been reported for these indications.[2]

The drug is a GABAA receptor α2 and α3 subunit-selective partial positive allosteric modulator acting via the benzodiazepine site.[2][1][3] It might have reduced side effects compared to non-selective high-efficacy positive allosteric modulators like the benzodiazepines diazepam and lorazepam.[4] In terms of chemical structure, AXS-17 is a cinnoline derivative.[1]

AXS-17 was originated by AstraZeneca and the University College London.[2] It was licensed and under development by Avenue Therapeutics's Baergic Bio, but was later acquired by Axsome Therapeutics, which is now developing the drug.[2][5] As of November 2025, AXS-17 is in phase 2 clinical trials for anxiety disorders and is in the preclinical research stage of development for absence epilepsy.[2] AXS-17 was first described in the scientific literature by at least 2012.[6][4]

See also

[edit]

References

[edit]
  1. 1 2 3 Maramai S, Benchekroun M, Ward SE, Atack JR (April 2020). "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry. 63 (7): 3425–3446. doi:10.1021/acs.jmedchem.9b01312. hdl:11365/1214874. PMID 31738537.
  2. 1 2 3 4 5 6 "BAER 101". AdisInsight. 14 November 2025. Retrieved 12 January 2026.
  3. 1 2 MacLean A, Chappell AS, Kranzler J, Evrard A, Monchal H, Roucard C (April 2024). "BAER-101, a selective potentiator of α2- and α3-containing GABAA receptors, fully suppresses spontaneous cortical spike-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg (GAERS)". Drug Development Research. 85 (2) e22160. doi:10.1002/ddr.22160. PMID 38380694.
  4. 1 2 Chen X, Jacobs G, de Kam M, Jaeger J, Lappalainen J, Maruff P, et al. (December 2014). "The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males". British Journal of Clinical Pharmacology. 78 (6): 1298–1314. doi:10.1111/bcp.12413. PMC 4256620. PMID 24802722.
  5. ↑ Incorvaia D (6 November 2025). "Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition". Fierce Biotech. Retrieved 12 January 2026.
  6. ↑ Zhou D, Sunzel M, Ribadeneira MD, Smith MA, Desai D, Lin J, et al. (July 2012). "A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison". British Journal of Clinical Pharmacology. 74 (1): 98–108. doi:10.1111/j.1365-2125.2011.04155.x. PMC 3394133. PMID 22122233.
Retrieved from "https://en.wikipedia.org/w/index.php?title=AXS-17&oldid=1344084465"